Current Report Filing (8-k)
December 12 2017 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December 12, 2017
PROVECTUS
BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Delaware
|
|
001-36457
|
|
90-0031917
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
10025
Investment Drive, Suite 250, Knoxville, TN 37932
(Address
of Principal Executive Offices)
(866)
594-5999
(Registrant’s
Telephone Number, Including Area Code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01. Regulation FD Disclosure.
On
December 12, 2017, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”)
announcing it reached a settlement with the United States Securities and Exchange Commission (the “SEC”) (the “SEC
settlement”) in connection with previously disclosed SEC investigations of two former Company executives and the Company.
Under
the terms of the SEC settlement, the Company, without admitting or denying the findings of the SEC, consented to the entry of
an administrative order that requires the Company to cease and desist from committing or causing any violations and any future
violations of Sections 13(a), 13(b)(2)(A), 13(b)(2)(B), and 14(a) of the Securities Exchange Act of 1934 and Rules 12b-20, 13a-1,
14a-3, and 14a-9 thereunder. The SEC did not allege fraud by the Company.
The
SEC noted in its settlement order that it had taken into consideration remedial acts promptly undertaken and cooperation afforded
to SEC staff by the Company.
A
copy of the Press Release is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference.
Pursuant
to the rules and regulations of the SEC, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information
set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange
Act of 1934, as amended.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
December 12, 2017
|
PROVECTUS
BIOPHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/
Timothy C. Scott
|
|
|
Timothy
C. Scott
|
|
|
President
|
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024